ユルトミリス薬の市場規模、シェア、動向分析レポート：適応症別、最終用途別、流通チャネル別、地域別、セグメント予測、2025年～2030年

ユルトミリス薬市場のサマリー

世界のユルトミリス薬市場規模は2024年に39億2,000万米ドルと推計され、2025年から2030年にかけて28.47%のCAGRで成長し、2030年には180億3,000万米ドルに達すると予測されます。世界のユルトミリス薬（ラブリズマブ）薬業界は、希少疾患の長時間作用型治療に対する需要の高まりにより、強い勢いを見せています。

前身であるソリリスと比較して、この薬剤は投与間隔が延長されているため、利便性が高く、患者のコンプライアンスが向上しています。このため、発作性夜間ヘモグロビン尿症（PNH）や非定型溶血性尿毒症症候群（aHUS）などの疾患を管理する医療従事者の間で嗜好が高まっています。アレクシオンは、米国および欧州を含む主要市場において、PNH患者の70％以上がソリリスからユルトミリス薬に移行したと報告しました。旧来の補体阻害剤からravulizumabへの移行は、市場全体の拡大に寄与しています。

さらに、全身型重症筋無力症（gMG）などの新たな適応症で臨床的有用性が拡大していることも、成長に拍車をかけています。例えば、2022年9月、ユルトミリス薬は欧州委員会から抗アセチルコリン受容体抗体陽性の重症筋無力症（gMG）成人患者の治療薬として承認を取得し、神経内科領域での地位を強化しています。

希少な自己免疫疾患や血液疾患の罹患率の上昇も、ユルトミリス薬の需要を促進する主な要因です。診断ツールの改善と臨床ガイドラインの更新により、対象となる患者集団が早期に特定されるようになりました。例えば、2024年3月、FDAは視神経脊髄炎スペクトラム障害（NMOSD）治療への使用の可能性についてユルトミリス薬に優先審査権を付与し、パイプラインの強さを強調しています。アストラゼネカとアレクシオンによる戦略的なマーケティング努力とパートナーシップは、臨床医や治療センターの認知度拡大に役立っています。これらの要素が組み合わさることで、2030年までの持続的な収益成長に向けた有利な環境が形成されています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ユルトミリス（ラブリズマブ）薬市場の変数、動向、範囲

• 市場系統の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ビジネス環境分析
  • 業界分析- ポーターのファイブフォース分析
  • PESTLE分析
  • パイプライン分析
  • 特許満了分析
  • 価格分析

第4章 ユルトミリス（ラブリズマブ）薬市場：適応症別ビジネス分析

• 適応症別市場シェア、2024年および2030年
• 適応症別セグメントダッシュボード
• 市場規模、予測、動向分析（適応症別、2018～2030年）
• 発作性夜間血色素尿症（PNH）
• 非典型溶血性尿毒症症候群（aHUS）
• 全身性重症筋無力症（gMG）
• 視神経脊髄炎スペクトラム障害（NMOSD）

第5章 ユルトミリス（ラブリズマブ）薬市場：最終用途別ビジネス分析

• 最終用途別市場シェア、2024年および2030年
• 最終用途別セグメントダッシュボード
• 市場規模、予測、動向分析（最終用途別、2018～2030年）
• アダルト
• 小児科

第6章 ユルトミリス（ラブリズマブ）薬市場：流通チャネル別ビジネス分析

• 流通チャネル別市場シェア、2024年および2030年
• 流通チャネル別セグメントダッシュボード
• 市場規模、予測、動向分析（流通チャネル別、2018～2030年）
• 病院薬局
• 小売薬局
• オンライン薬局

第7章 ユルトミリス（ラブリズマブ）薬市場：地域別推定・動向分析

• 地域別市場シェア分析、2024年および2030年
• 地域別市場ダッシュボード
• 市場規模と予測動向分析、2018年から2030年まで：
• 北米
  • 国別、2018年～2030年
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東およびアフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 戦略マッピング
• 企業プロファイル/上場企業
  • AstraZeneca

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 Global Ultomiris (ravulizumab) market, by region, 2018 - 2030 (USD Million)
• Table 4 Global Ultomiris (ravulizumab) market, by indication, 2018 - 2030 (USD Million)
• Table 5 Global Ultomiris (ravulizumab) market, by end use, 2018 - 2030 (USD Million)
• Table 6 Global Ultomiris (ravulizumab) market, by distribution channel, 2018 - 2030 (USD Million)
• Table 7 North America Ultomiris (ravulizumab) market, by country, 2018 - 2030 (USD Million)
• Table 8 North America Ultomiris (ravulizumab) market, by indication, 2018 - 2030 (USD Million)
• Table 9 North America Ultomiris (ravulizumab) market, by end use, 2018 - 2030 (USD Million)
• Table 10 North America Ultomiris (ravulizumab) market, by distribution channel, 2018 - 2030 (USD Million)
• Table 11 U.S. Ultomiris (ravulizumab) market, by indication, 2018 - 2030 (USD Million)
• Table 12 U.S. Ultomiris (ravulizumab) market, by end use, 2018 - 2030 (USD Million)
• Table 13 U.S. Ultomiris (ravulizumab) market, by distribution channel, 2018 - 2030 (USD Million)
• Table 14 Canada Ultomiris (ravulizumab) market, by indication, 2018 - 2030 (USD Million)
• Table 15 Canada Ultomiris (ravulizumab) market, by end use, 2018 - 2030 (USD Million)
• Table 16 Canada Ultomiris (ravulizumab) market, by distribution channel, 2018 - 2030 (USD Million)
• Table 17 Mexico Ultomiris (ravulizumab) market, by indication, 2018 - 2030 (USD Million)
• Table 18 Mexico Ultomiris (ravulizumab) market, by end use, 2018 - 2030 (USD Million)
• Table 19 Mexico Ultomiris (ravulizumab) market, by distribution channel, 2018 - 2030 (USD Million)
• Table 20 Europe Ultomiris (ravulizumab) market, by country, 2018 - 2030 (USD Million)
• Table 21 Europe Ultomiris (ravulizumab) market, by indication, 2018 - 2030 (USD Million)
• Table 22 Europe Ultomiris (ravulizumab) market, by end use, 2018 - 2030 (USD Million)
• Table 23 Europe Ultomiris (ravulizumab) market, by distribution channel, 2018 - 2030 (USD Million)
• Table 24 UK Ultomiris (ravulizumab) market, by indication, 2018 - 2030 (USD Million)
• Table 25 UK Ultomiris (ravulizumab) market, by end use, 2018 - 2030 (USD Million)
• Table 26 UK Ultomiris (ravulizumab) market, by distribution channel, 2018 - 2030 (USD Million)
• Table 27 Germany Ultomiris (ravulizumab) market, by indication, 2018 - 2030 (USD Million)
• Table 28 Germany Ultomiris (ravulizumab) market, by end use, 2018 - 2030 (USD Million)
• Table 29 Germany Ultomiris (ravulizumab) market, by distribution channel, 2018 - 2030 (USD Million)
• Table 30 France Ultomiris (ravulizumab) market, by indication, 2018 - 2030 (USD Million)
• Table 31 France Ultomiris (ravulizumab) market, by end use, 2018 - 2030 (USD Million)
• Table 32 France Ultomiris (ravulizumab) market, by distribution channel, 2018 - 2030 (USD Million)
• Table 33 Italy Ultomiris (ravulizumab) market, by indication, 2018 - 2030 (USD Million)
• Table 34 Italy Ultomiris (ravulizumab) market, by end use, 2018 - 2030 (USD Million)
• Table 35 Italy Ultomiris (ravulizumab) market, by distribution channel, 2018 - 2030 (USD Million)
• Table 36 Spain Ultomiris (ravulizumab) market, by indication, 2018 - 2030 (USD Million)
• Table 37 Spain Ultomiris (ravulizumab) market, by end use, 2018 - 2030 (USD Million)
• Table 38 Spain Ultomiris (ravulizumab) market, by distribution channel, 2018 - 2030 (USD Million)
• Table 39 Norway Ultomiris (ravulizumab) market, by indication, 2018 - 2030 (USD Million)
• Table 40 Norway Ultomiris (ravulizumab) market, by end use, 2018 - 2030 (USD Million)
• Table 41 Norway Ultomiris (ravulizumab) market, by distribution channel, 2018 - 2030 (USD Million)
• Table 42 Denmark Ultomiris (ravulizumab) market, by indication, 2018 - 2030 (USD Million)
• Table 43 Denmark Ultomiris (ravulizumab) market, by end use, 2018 - 2030 (USD Million)
• Table 44 Denmark Ultomiris (ravulizumab) market, by distribution channel, 2018 - 2030 (USD Million)
• Table 45 Sweden Ultomiris (ravulizumab) market, by indication, 2018 - 2030 (USD Million)
• Table 46 Sweden Ultomiris (ravulizumab) market, by end use, 2018 - 2030 (USD Million)
• Table 47 Sweden Ultomiris (ravulizumab) market, by distribution channel, 2018 - 2030 (USD Million)
• Table 48 Asia Pacific Ultomiris (ravulizumab) market, by country, 2018 - 2030 (USD Million)
• Table 49 Asia Pacific Ultomiris (ravulizumab) market, by indication, 2018 - 2030 (USD Million)
• Table 50 Asia Pacific Ultomiris (ravulizumab) market, by end use, 2018 - 2030 (USD Million)
• Table 51 Asia Pacific Ultomiris (ravulizumab) market, by distribution channel, 2018 - 2030 (USD Million)
• Table 52 Japan Ultomiris (ravulizumab) market, by indication, 2018 - 2030 (USD Million)
• Table 53 Japan Ultomiris (ravulizumab) market, by end use, 2018 - 2030 (USD Million)
• Table 54 Japan Ultomiris (ravulizumab) market, by distribution channel, 2018 - 2030 (USD Million)
• Table 55 China Ultomiris (ravulizumab) market, by indication, 2018 - 2030 (USD Million)
• Table 56 China Ultomiris (ravulizumab) market, by end use, 2018 - 2030 (USD Million)
• Table 57 China Ultomiris (ravulizumab) market, by distribution channel, 2018 - 2030 (USD Million)
• Table 58 India Ultomiris (ravulizumab) market, by indication, 2018 - 2030 (USD Million)
• Table 59 India Ultomiris (ravulizumab) market, by end use, 2018 - 2030 (USD Million)
• Table 60 India Ultomiris (ravulizumab) market, by distribution channel, 2018 - 2030 (USD Million)
• Table 61 Australia Ultomiris (ravulizumab) market, by indication, 2018 - 2030 (USD Million)
• Table 62 Australia Ultomiris (ravulizumab) market, by end use, 2018 - 2030 (USD Million)
• Table 63 Australia Ultomiris (ravulizumab) market, by distribution channel, 2018 - 2030 (USD Million)
• Table 64 South Korea Ultomiris (ravulizumab) market, by indication, 2018 - 2030 (USD Million)
• Table 65 South Korea Ultomiris (ravulizumab) market, by end use, 2018 - 2030 (USD Million)
• Table 66 South Korea Ultomiris (ravulizumab) market, by distribution channel, 2018 - 2030 (USD Million)
• Table 67 Thailand Ultomiris (ravulizumab) market, by indication, 2018 - 2030 (USD Million)
• Table 68 Thailand Ultomiris (ravulizumab) market, by end use, 2018 - 2030 (USD Million)
• Table 69 Thailand Ultomiris (ravulizumab) market, by distribution channel, 2018 - 2030 (USD Million)
• Table 70 Latin America Ultomiris (ravulizumab) market, by country, 2018 - 2030 (USD Million)
• Table 71 Latin America Ultomiris (ravulizumab) market, by indication, 2018 - 2030 (USD Million)
• Table 72 Latin America Ultomiris (ravulizumab) market, by end use, 2018 - 2030 (USD Million)
• Table 73 Latin America Ultomiris (ravulizumab) market, by distribution channel, 2018 - 2030 (USD Million)
• Table 74 Brazil Ultomiris (ravulizumab) market, by indication, 2018 - 2030 (USD Million)
• Table 75 Brazil Ultomiris (ravulizumab) market, by end use, 2018 - 2030 (USD Million)
• Table 76 Brazil Ultomiris (ravulizumab) market, by distribution channel, 2018 - 2030 (USD Million)
• Table 77 Argentina Ultomiris (ravulizumab) market, by indication, 2018 - 2030 (USD Million)
• Table 78 Argentina Ultomiris (ravulizumab) market, by end use, 2018 - 2030 (USD Million)
• Table 79 Argentina Ultomiris (ravulizumab) market, by distribution channel, 2018 - 2030 (USD Million)
• Table 80 Middle East & Africa Ultomiris (ravulizumab) market, by country, 2018 - 2030 (USD Million)
• Table 81 Middle East & Africa Ultomiris (ravulizumab) market, by indication, 2018 - 2030 (USD Million)
• Table 82 Middle East & Africa Ultomiris (ravulizumab) market, by end use, 2018 - 2030 (USD Million)
• Table 83 Middle East & Africa Ultomiris (ravulizumab) market, by distribution channel, 2018 - 2030 (USD Million)
• Table 84 South Africa Ultomiris (ravulizumab) market, by indication, 2018 - 2030 (USD Million)
• Table 85 South Africa Ultomiris (ravulizumab) market, by end use, 2018 - 2030 (USD Million)
• Table 86 South Africa Ultomiris (ravulizumab) market, by distribution channel, 2018 - 2030 (USD Million)
• Table 87 Saudi Arabia Ultomiris (ravulizumab) market, by indication, 2018 - 2030 (USD Million)
• Table 88 Saudi Arabia Ultomiris (ravulizumab) market, by end use, 2018 - 2030 (USD Million)
• Table 89 Saudi Arabia Ultomiris (ravulizumab) market, by distribution channel, 2018 - 2030 (USD Million)
• Table 90 UAE Ultomiris (ravulizumab) market, by indication, 2018 - 2030 (USD Million)
• Table 91 UAE Ultomiris (ravulizumab) market, by end use, 2018 - 2030 (USD Million)
• Table 92 UAE Ultomiris (ravulizumab) market, by distribution channel, 2018 - 2030 (USD Million)
• Table 93 Kuwait Ultomiris (ravulizumab) market, by indication, 2018 - 2030 (USD Million)
• Table 94 Kuwait Ultomiris (ravulizumab) market, by end use, 2018 - 2030 (USD Million)
• Table 95 Kuwait Ultomiris (ravulizumab) market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Ultomiris (ravulizumab) drug market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Therapeutic approach and application outlook (USD Million)
• Fig. 10 Competitive landscape
• Fig. 11 Ultomiris (ravulizumab) drug market dynamics
• Fig. 12 Ultomiris (ravulizumab) drug market: Porter's five forces analysis
• Fig. 13 Ultomiris (ravulizumab) drug market: PESTLE analysis
• Fig. 14 Indication market, 2018 - 2030 (USD Million)
• Fig. 15 Paroxysmal Nocturnal Hemoglobinuria (PNH) market, 2018 - 2030 (USD Million)
• Fig. 16 Atypical Hemolytic Uremic Syndrome (aHUS) market, 2018 - 2030 (USD Million)
• Fig. 17 Generalized Myasthenia Gravis (gMG) market, 2018 - 2030 (USD Million)
• Fig. 18 Neuromyelitis Optica Spectrum Disorder (NMOSD) market, 2018 - 2030 (USD Million)
• Fig. 19 End Use market, 2018 - 2030 (USD Million)
• Fig. 20 Adult market, 2018 - 2030 (USD Million)
• Fig. 21 Pediatric market, 2018 - 2030 (USD Million)
• Fig. 22 Distribution Channel market, 2018 - 2030 (USD Million)
• Fig. 23 Hospital Pharmacies market, 2018 - 2030 (USD Million)
• Fig. 24 Retail Pharmacies market, 2018 - 2030 (USD Million)
• Fig. 25 Online Pharmacies market, 2018 - 2030 (USD Million)
• Fig. 26 Ultomiris (ravulizumab) market revenue, by region
• Fig. 27 Regional marketplace: Key takeaways
• Fig. 28 North America Ultomiris (ravulizumab) market, 2018 - 2030 (USD Million)
• Fig. 29 U.S. country dynamics
• Fig. 30 U.S. Ultomiris (ravulizumab) market, 2018 - 2030 (USD Million)
• Fig. 31 Canada country dynamics
• Fig. 32 Canada Ultomiris (ravulizumab) market, 2018 - 2030 (USD Million)
• Fig. 33 Mexico country dynamics
• Fig. 34 Mexico Ultomiris (ravulizumab) market, 2018 - 2030 (USD Million)
• Fig. 35 Europe Ultomiris (ravulizumab) market, 2018 - 2030 (USD Million)
• Fig. 36 UK country dynamics
• Fig. 37 UK Ultomiris (ravulizumab) market, 2018 - 2030 (USD Million)
• Fig. 38 Germany country dynamics
• Fig. 39 Germany Ultomiris (ravulizumab) market, 2018 - 2030 (USD Million)
• Fig. 40 France country dynamics
• Fig. 41 France Ultomiris (ravulizumab) market, 2018 - 2030 (USD Million)
• Fig. 42 Italy country dynamics
• Fig. 43 Italy Ultomiris (ravulizumab) market, 2018 - 2030 (USD Million)
• Fig. 44 Spain country dynamics
• Fig. 45 Spain Ultomiris (ravulizumab) market, 2018 - 2030 (USD Million)
• Fig. 46 Norway country dynamics
• Fig. 47 Norway Ultomiris (ravulizumab) market, 2018 - 2030 (USD Million)
• Fig. 48 Sweden country dynamics
• Fig. 49 Sweden Ultomiris (ravulizumab) market, 2018 - 2030 (USD Million)
• Fig. 50 Denmark country dynamics
• Fig. 51 Denmark Ultomiris (ravulizumab) market, 2018 - 2030 (USD Million)
• Fig. 52 Asia Pacific Ultomiris (ravulizumab) market, 2018 - 2030 (USD Million)
• Fig. 53 Japan country dynamics
• Fig. 54 Japan Ultomiris (ravulizumab) market, 2018 - 2030 (USD Million)
• Fig. 55 China country dynamics
• Fig. 56 China Ultomiris (ravulizumab) market, 2018 - 2030 (USD Million)
• Fig. 57 India country dynamics
• Fig. 58 India Ultomiris (ravulizumab) market, 2018 - 2030 (USD Million)
• Fig. 59 Australia country dynamics
• Fig. 60 Australia Ultomiris (ravulizumab) market, 2018 - 2030 (USD Million)
• Fig. 61 South Korea country dynamics
• Fig. 62 South Korea Ultomiris (ravulizumab) market, 2018 - 2030 (USD Million)
• Fig. 63 Thailand country dynamics
• Fig. 64 Thailand Ultomiris (ravulizumab) market, 2018 - 2030 (USD Million)
• Fig. 65 Latin America Ultomiris (ravulizumab) market, 2018 - 2030 (USD Million)
• Fig. 66 Brazil country dynamics
• Fig. 67 Brazil Ultomiris (ravulizumab) market, 2018 - 2030 (USD Million)
• Fig. 68 Argentina country dynamics
• Fig. 69 Argentina Ultomiris (ravulizumab) market, 2018 - 2030 (USD Million)
• Fig. 70 MEA Ultomiris (ravulizumab) market, 2018 - 2030 (USD Million)
• Fig. 71 South Africa country dynamics
• Fig. 72 South Africa Ultomiris (ravulizumab) market, 2018 - 2030 (USD Million)
• Fig. 73 Saudi Arabia country dynamics
• Fig. 74 Saudi Arabia Ultomiris (ravulizumab) market, 2018 - 2030 (USD Million)
• Fig. 75 UAE country dynamics
• Fig. 76 UAE Ultomiris (ravulizumab) market, 2018 - 2030 (USD Million)
• Fig. 77 Kuwait country dynamics
• Fig. 78 Kuwait Ultomiris (ravulizumab) market, 2018 - 2030 (USD Million)
• Fig. 79 Company categorization
• Fig. 80 Company market position analysis
• Fig. 81 Strategic framework

Ultomiris Drug Market Summary

The global ultomiris drug market size was estimated at USD 3.92 billion in 2024 and is projected to reach USD 18.03 billion by 2030, growing at a CAGR of 28.47% from 2025 to 2030. The global Ultomiris (ravulizumab) drug industry is experiencing strong momentum due to the rising demand for long-acting treatments in rare disorders.

Compared to its predecessor, Soliris, the drug's extended dosing interval offers convenience and improved patient compliance. This has increased preference among healthcare providers managing conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Alexion reported that over 70% of PNH patients had transitioned to Ultomiris from Soliris in major markets, including the U.S. and EU. The transition from older complement inhibitors to ravulizumab contributes to overall market expansion.

Growth is further fueled by its expanding clinical utility across new indications such as generalized myasthenia gravis (gMG). For instance, in September 2022, Ultomiris received approval from the European Commission to treat adult patients with anti-acetylcholine receptor antibody-positive gMG, strengthening its position in the neurology segment.

The rising incidence of rare autoimmune and hematologic conditions is also a major factor driving demand for Ultomiris. Improved diagnostic tools and updated clinical guidelines have identified eligible patient populations earlier. For instance, in March 2024, the FDA granted priority review to Ultomiris for its potential use in treating neuromyelitis optica spectrum disorder (NMOSD), highlighting its pipeline strength. Strategic marketing efforts and partnerships by AstraZeneca and Alexion have helped expand awareness among clinicians and treatment centers. These combined elements shape a favorable environment for sustained revenue growth through 2030.

Global Ultomiris Drug Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global Ultomiris (ravulizumab) drug market report based on indication, end use, distribution channel, and region:

• Indication Outlook (Revenue, USD Million, 2018 - 2030)
• Paroxysmal Nocturnal Hemoglobinuria (PNH)
• Atypical Hemolytic Uremic Syndrome (aHUS)
• Generalized Myasthenia Gravis (gMG)
• Neuromyelitis Optica Spectrum Disorder (NMOSD)
• End Use Outlook (Revenue, USD Million, 2018 - 2030)
• Adult
• Pediatric
• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Indication
  • 1.2.2. End Use
  • 1.2.3. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Ultomiris (Ravulizumab) Drug Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Ultomiris (Ravulizumab) Drug Market: Indication Business Analysis

• 4.1. Indication Market Share, 2024 & 2030
• 4.2. Indication Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
• 4.4. Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • 4.4.1. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, 2018 - 2030 (USD Million)
• 4.5. Atypical Hemolytic Uremic Syndrome (aHUS)
  • 4.5.1. Atypical Hemolytic Uremic Syndrome (aHUS) Market, 2018 - 2030 (USD Million)
• 4.6. Generalized Myasthenia Gravis (gMG)
  • 4.6.1. Generalized Myasthenia Gravis (gMG) Market, 2018 - 2030 (USD Million)
• 4.7. Neuromyelitis Optica Spectrum Disorder (NMOSD)
  • 4.7.1. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market, 2018 - 2030 (USD Million)

Chapter 5. Ultomiris (Ravulizumab) Drug Market: End Use Business Analysis

• 5.1. End Use Market Share, 2024 & 2030
• 5.2. End Use Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 5.4. Adult
  • 5.4.1. Adult Market, 2018 - 2030 (USD Million)
• 5.5. Pediatric
  • 5.5.1. Pediatric Market, 2018 - 2030 (USD Million)

Chapter 6. Ultomiris (Ravulizumab) Drug Market: Distribution Channel Business Analysis

• 6.1. Distribution Channel Market Share, 2024 & 2030
• 6.2. Distribution Channel Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 6.4. Hospital Pharmacies
  • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
• 6.5. Retail Pharmacies
  • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
• 6.6. Online Pharmacies
  • 6.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 7. Ultomiris (Ravulizumab) Drug Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. North America Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Target Disease Prevalence
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Framework
    • 7.4.2.5. U.S. Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Target Disease Prevalence
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Framework
    • 7.4.3.5. U.S. Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Target Disease Prevalence
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Framework
    • 7.4.4.5. Mexico Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Target Disease Prevalence
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Framework
    • 7.5.2.5. Uk Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Target Disease Prevalence
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Framework
    • 7.5.3.5. Germany Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Target Disease Prevalence
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement Framework
    • 7.5.4.5. France Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Target Disease Prevalence
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Reimbursement Framework
    • 7.5.5.5. Italy Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Target Disease Prevalence
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Reimbursement Framework
    • 7.5.6.5. Spain Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Target Disease Prevalence
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Reimbursement Framework
    • 7.5.7.5. Denmark Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Target Disease Prevalence
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Reimbursement Framework
    • 7.5.8.5. Sweden Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Target Disease Prevalence
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Reimbursement Framework
    • 7.5.9.5. Norway Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Target Disease Prevalence
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Framework
    • 7.6.2.5. Japan Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Target Disease Prevalence
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Framework
    • 7.6.3.5. China Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Target Disease Prevalence
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Framework
    • 7.6.4.5. India Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Target Disease Prevalence
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Framework
    • 7.6.5.5. Australia Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Target Disease Prevalence
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement Framework
    • 7.6.6.5. South Korea Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Target Disease Prevalence
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement Framework
    • 7.6.7.5. Thailand Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Target Disease Prevalence
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement Framework
    • 7.7.2.5. Japan Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Target Disease Prevalence
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement Framework
    • 7.7.3.5. China Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. Middle East and Africa
  • 7.8.1. Middle East and Africa Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2017 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Target Disease Prevalence
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement Framework
    • 7.8.2.5. South Africa Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Target Disease Prevalence
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement Framework
    • 7.8.3.5. Saudi Arabia Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Target Disease Prevalence
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. Reimbursement Framework
    • 7.8.4.5. UAE Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Target Disease Prevalence
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Reimbursement Framework
    • 7.8.5.5. Kuwait Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Strategy Mapping
• 8.2. Company Profiles/Listing
  • 8.2.1. AstraZeneca
    • 8.2.1.1. Overview
    • 8.2.1.2. Financial Performance
    • 8.2.1.3. Product Benchmarking
    • 8.2.1.4. Strategic Initiatives